These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 9723821)

  • 1. Gastrointestinal tolerability of meloxicam and piroxicam: a double-blind placebo-controlled study.
    Lipscomb GR; Wallis N; Armstrong G; Rees WD
    Br J Clin Pharmacol; 1998 Aug; 46(2):133-7. PubMed ID: 9723821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 4-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers.
    Patoia L; Santucci L; Furno P; Dionisi MS; Dell'Orso S; Romagnoli M; Sattarinia A; Marini MG
    Br J Rheumatol; 1996 Apr; 35 Suppl 1():61-7. PubMed ID: 8630640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of endoscopic gastric mucosa features after administration of piroxicam to meloxicam and their correlation with dyspepsia symptoms in elderly patient with knee osteoarthritis.
    Girawan D; Abdurachman SA; Djumhana A; Roslia J; Pramudiyo R
    Acta Med Indones; 2004; 36(4):202-6. PubMed ID: 15673949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endoscopic comparison of the gastroduodenal safety and the effects on arachidonic acid products between meloxicam and piroxicam in the treatment of osteoarthritis.
    Chang DM; Young TH; Hsu CT; Kuo SY; Hsieh TC
    Clin Rheumatol; 2001; 20(2):104-13. PubMed ID: 11346221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis.
    Dequeker J; Hawkey C; Kahan A; Steinbrück K; Alegre C; Baumelou E; Bégaud B; Isomäki H; Littlejohn G; Mau J; Papazoglou S
    Br J Rheumatol; 1998 Sep; 37(9):946-51. PubMed ID: 9783758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects on gastroduodenal mucosa of a new nonsteroidal anti-inflammatory drug, amtolmetin-guacyl, versus piroxicam in healthy volunteers: a short-term, double-blind, endoscopically controlled study.
    Lazzaroni M; Anderloni A; Bianchi Porro G
    Eur J Gastroenterol Hepatol; 2001 Jul; 13(7):833-9. PubMed ID: 11474314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of oxicam inhibitors of cyclooxygenase on oxidative stress generation in rat gastric mucosa. A comparative study.
    Villegas I; Martín MJ; La Casa C; Motilva V; De La Lastra CA
    Free Radic Res; 2002 Jul; 36(7):769-77. PubMed ID: 12180128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucosal damage induced by preferential COX-1 and COX-2 inhibitors: role of prostaglandins and inflammatory response.
    Villegas I; La Casa C; de la Lastra CA; Motilva V; Herrerías JM; Martín MJ
    Life Sci; 2004 Jan; 74(7):873-84. PubMed ID: 14659976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastric damage induced by subchronic administration of preferential cyclooxygenase-1 and cyclooxygenase-2 inhibitors in rats.
    Villegas I; Alarcón de la Lastra C; Martín MJ; Motilva V; La Casa García C
    Pharmacology; 2002 Oct; 66(2):68-75. PubMed ID: 12207113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe gastric mucosal damage induced by NSAIDs in healthy subjects is associated with Helicobacter pylori infection and high levels of serum pepsinogens.
    Santucci L; Fiorucci S; Patoia L; Di Matteo FM; Brunori PM; Morelli A
    Dig Dis Sci; 1995 Sep; 40(9):2074-80. PubMed ID: 7555467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial.
    Dougados M; Gueguen A; Nakache JP; Velicitat P; Veys EM; Zeidler H; Calin A
    Rheumatology (Oxford); 1999 Mar; 38(3):235-44. PubMed ID: 10325662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of firocoxib, meloxicam, and tepoxalin administration on eicosanoid production in target tissues of healthy cats.
    Goodman LA; Torres BT; Reynolds LR; Budsberg SC
    Am J Vet Res; 2010 Sep; 71(9):1067-73. PubMed ID: 20807147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meloxicam in acute episodes of soft-tissue rheumatism of the shoulder.
    Vidal L; Kneer W; Baturone M; Sigmund R
    Inflamm Res; 2001 Mar; 50 Suppl 1():S24-9. PubMed ID: 11339517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute gastrointestinal permeability responses to different non-steroidal anti-inflammatory drugs.
    Smecuol E; Bai JC; Sugai E; Vazquez H; Niveloni S; Pedreira S; Mauriño E; Meddings J
    Gut; 2001 Nov; 49(5):650-5. PubMed ID: 11600467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of food intake and oxidative stress on intestinal lesions caused by meloxicam and piroxicam in rats.
    Villegas I; Alarcón de la Lastra C; La Casa C; Motilva V; Martín MJ
    Eur J Pharmacol; 2001 Feb; 414(1):79-86. PubMed ID: 11230998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip.
    Lindén B; Distel M; Bluhmki E
    Br J Rheumatol; 1996 Apr; 35 Suppl 1():35-8. PubMed ID: 8630634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam.
    Singh G; Lanes S; Triadafilopoulos G
    Am J Med; 2004 Jul; 117(2):100-6. PubMed ID: 15234645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of faecal blood loss, upper gastrointestinal mucosal integrity and symptoms after piroxicam beta-cyclodextrin, piroxicam and placebo administration.
    Patoia L; Clausi G; Farroni F; Alberti P; Fugiani P; Bufalino L
    Eur J Clin Pharmacol; 1989; 36(6):599-604. PubMed ID: 2673795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The risk of gastrointestinal bleed, myocardial infarction, and newly diagnosed hypertension in users of meloxicam, diclofenac, naproxen, and piroxicam.
    Jick SS
    Pharmacotherapy; 2000 Jul; 20(7):741-4. PubMed ID: 10907963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Protective effect of ranitidine in the stomach and duodenum against piroxicam. An endoscopy controlled double-blind study].
    Müller P; Simon B
    Arzneimittelforschung; 1992 Dec; 42(12):1492-4. PubMed ID: 1288514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.